Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHuiyu Li

Discussion

Loading...

Member takes

Overview

Pilot study shows improved success and quality of life in patients with severe aplastic anemia post-transplant, suggesting effective management of graft-versus-host disease.

Key Points

  • This pilot study aims to investigate the efficacy and safety of a novel reduced-toxicity conditioning regimen for severe aplastic anemia.
  • Patients with severe aplastic anemia underwent allogeneic hematopoietic stem cell transplantation as first-line therapy.
  • A novel conditioning regimen included busulfan, fludarabine, cyclophosphamide, and anti-thymocyte globulin.
  • Graft-versus-host disease prophylaxis employed cyclosporine, mycophenolate mofetil, and additional agents.
  • All patients achieved sustained engraftment with a median follow-up of 47.6 months.
  • The median engraftment time for white blood cells and platelets was 13 and 19 days, respectively.
  • Most patients had durable disease-free survival, with acceptable quality of life and minimal chronic graft-versus-host disease.

Cite This Study

Huiyu Li (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d01ehttps://doi.org/10.1182/blood-2025-7735
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study2025
  2. 2The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.2025
  3. 3Impact of pre- and post-transplant transfusion requirements on outcomes in severe aplastic anemia patients2025
  4. 4Outcomes of omidubicel-expanded umbilical cord blood transplantation in patients with severe aplastic anemia2025
  5. 5No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation2025